Pharvaris NV at JPMorgan Healthcare Conference Transcript
Good morning, everybody, and welcome to the final day of the JPMorgan Healthcare Conference 2024. The next presentation is by Pharvaris, and I'm pleased to introduce to the stage the CEO, Berndt Modig.
Thank you. So good morning, everybody. Nice to be here and also good afternoon or good evening for those of you on the webcast, depending on where you are. And also, thanks to JPMorgan for the opportunity to present. I'm also joined today by my team, Peng Lu, our Chief Medical Officer; Wim Souverijns, our Community Engagement and Commercial Officer; and Morgan Conn, our Chief Business Officer, which will join us later for the Q&A part.
So, I will be making some forward-looking statements. So, I refer you also to our SEC filings in our website, including the risk factors.
So, deucrictibant, that's our lead asset. That's a novel, orally available bradykinin B2 receptor antagonist for bradykinin mediated angioedema. I'm proud to say also that to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
